DIGNITANA FUELS GROWTH WITH NINE NEW INSTALLATIONS IN U.S. FOR DigniCap® SCALP COOLING MEDICAL DEVICE
Lund, Sweden – February 22, 2017—Dignitana, a global leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared in December 2015 by the FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will soon be available in nine additional medical centers across the United States including the four locations of University of Miami Health System that were contracted in November 2016.
The DigniCap® system is the first scalp cooling device to complete rigorous FDA clinical trials in America, where seven out of ten patients with early-stage breast cancer kept at least 50% of their hair. Dignitana continues to rapidly expand its reach across the U.S. as demand for the medical device accelerates, securing contracts with 57 medical centers across 18 states.
The following cancer treatment centers are the most recent U.S. sites to include the DigniCap® scalp cooling system as part of their breast cancer treatment and care regimens:
Greenville, South Carolina
Charlotte, North Carolina
Lone Tree, Colorado
Coral Gables, Florida
“Demand for DigniCap in the U.S. continues to build—especially after the recent publication of such positive study results in the Journal of the American Medical Association,” said William Cronin, Chief Executive Officer of Dignitana, Inc., the U.S. subsidiary of Dignitana AB. “We are pleased and honored to be able to work with so many patient-focused medical centers and have the opportunity to help them provide their breast cancer patients with the only FDA-cleared medical device to reduce hair loss while undergoing chemotherapy.”
The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.
About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Adviser. Headquartered in Dallas, Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For more information visit www.dignitana.com.
The information in this press release is such that Dignitana AB must disclose it in accordance with the EU market abuse regulation. The information was submitted, by the above contact, for publication at 14.00 (CET), February 22, 2017.
Caren Browning Semmy Rülf
King + Company Chairman of the board, Dignitana AB
00 1 212 561-7464 +46 (0)709-312730